Connor, Clark & Lunn Investment Management (CC&L)’s Seres Therapeutics MCRB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-3,504
| Closed | -$450K | – | 1346 |
|
|
2022
Q3 | $450K | Buy |
3,504
+854
| +32% | +$110K | ﹤0.01% | 833 |
|
|
2022
Q2 | $182K | Sell |
2,650
-6,154
| -70% | -$423K | ﹤0.01% | 943 |
|
|
2022
Q1 | $1.25M | Sell |
8,804
-2,094
| -19% | -$298K | 0.01% | 617 |
|
|
2021
Q4 | $1.82M | Buy |
10,898
+8,499
| +354% | +$1.42M | 0.01% | 553 |
|
|
2021
Q3 | $334K | Buy |
2,399
+816
| +52% | +$114K | ﹤0.01% | 849 |
|
|
2021
Q2 | $755K | Buy |
+1,583
| New | +$755K | ﹤0.01% | 711 |
|
|
2019
Q2 | – | Sell |
-855
| Closed | -$117K | – | 1044 |
|
|
2019
Q1 | $117K | Buy |
855
+30
| +4% | +$4.11K | ﹤0.01% | 858 |
|
|
2018
Q4 | $75K | Buy |
825
+25
| +3% | +$2.27K | ﹤0.01% | 913 |
|
|
2018
Q3 | $121K | Buy |
800
+120
| +18% | +$18.2K | ﹤0.01% | 880 |
|
|
2018
Q2 | $117K | Buy |
+680
| New | +$117K | ﹤0.01% | 988 |
|
|
2017
Q2 | – | Sell |
-1,893
| Closed | -$427K | – | 885 |
|
|
2017
Q1 | $427K | Buy |
1,893
+1,139
| +151% | +$257K | ﹤0.01% | 654 |
|
|
2016
Q4 | $149K | Buy |
+754
| New | +$149K | ﹤0.01% | 816 |
|